A multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer

Chemotherapy

Volumn 53, Issue 6, 2007, Pages 454-460

  Fahlke, J ^a,h   Ridwelski, K ^b   Schmidt, C ^a   Hribaschek, K ^a   Stuebs, P ^a   Kettner, E ^c   Quietzsch, D ^d   Assmann, M ^e   Deist, T ^f   Keilholz, U ^g   Lippert, H ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Hospital Magdeburg   (Germany)

^c Hospital Magdeburg   (Germany)

^d Hospital Chemnitz   (Germany)

^e Krankenhaus Riesa   (Germany)

^f Augenarztpraxis Aschersleben Dres Steindel and Steindel Partnerschaft   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Gastric cancer

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NERVOUS SYSTEM TOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 36049028074     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110042     Document Type: Article

References (21)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
4. Glimelius B, Ekstrom K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
5. Dickson JL, Cunningham D: Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 2004;16:255-263.
6. Diaz-Rubio E: New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 2004;9:282-294.
7. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-2657.
8. Waters JS, Norman A, Cunningham D, et al: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999;80:269-272.
9. Wang X, Pang L, Feng J: A phase II study of etoposide, doxorubicin, and carboplatin in the treatment of advanced gastric cancer. Am J Clin Oncol 2002;25:71-75.
10. Roth AD, Herrmann R, Morant R, et al: Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 1998;34:2126-2128.
11. Van Cutsem E: The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 2004;9(suppl 2):9-15.
12. Mai M, Sakata Y, Kanamaru R, et al: A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a Cooperative Study Group trial (group B) (in Japanese). Jpn J Cancer Chemother 1999;26:487-496.
13. Ridwelski K, Gebauer T, Fahlke J, et al: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:47-51.
14. Roth AD, Maibach R, Martinelli G, et al: Docetaxel (taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO). Ann Oncol 2000;11:301-316.
15. Saitoh S, Sakata Y: Docetaxel and cisplatin in patients with advanced gastric cancer: results of Japanese phase I/II study. Gastric Cancer 2002;5(suppl 1):23-26.
16. Balzer-Kubiczek EK, Attarpour M, et al: Cytotoxicity of docetaxel (Taxotere®) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells. Chemotherapy 2006;52:231-240.
17. Yilmaz U, Oztop I, et al: Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. Chemotherapy 2006;52:264-270.
18. Ajani JA, Fodor MB, Tjulandin SA, et al: A multi-institutional phase II randomized trial of docetaxel plus cisplatin (DC) or DC plus 5-fluorouracil (DCF) in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:5660-5667.
19. Moiseyenko VM, Ajani JA, Tjulandin SA, et al: Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC) (abstract 4002). J Clin Oncol 2005;23:308.
20. Roth AD, Maibach R, Fazio N, et al: 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol 2004;15:759-764.
21. Roth AD, Maibach R, Falk S, et al: Docetaxel-cisplatin-5-FU (TCF) versus docetaxelcisplatin (TC) versus epirubicin-cisplatin-5-FU (ECF) as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK) (abstract 4020). Proc Am Soc Clin Oncol 2004;22:377.